Research Progress of the Combination of Metformin and SGLT2 Inhibitors in the Treatment of PCOS Complicated with T2DM
Polycystic ovary syndrome(PCOS)patients are often complicated by type 2 diabetes mellitus(T2DM),and the two are related and influence each other in etiology and pathogenesis.Metformin is the basic drug for T2DM and is also clinically used for PCOS.However,the therapeutic effect of Metformin alone is limited,and the combination with other drugs has become an important treatment choice.Sodium-glucose cotransporter 2(SGLT2)inhibitors,as a class of drugs with a unique mechanism of action,have a good therapeutic effect and a broad application range.Now,considering metformin combined with SGLT2 inhibitors in the treatment of PCOS combined with T2DM patients,this article reviews the research progress and mechanism of metformin combined with SGLT2 inhibitors in the treatment of PCOS combined with T2DM patients.
国家科技期刊平台
NSTL
万方数据
